Bullish Movements – Genetic Technologies Limited (ADR) (NASDAQ:GENE), Theravance Inc(NASDAQ:THRX), Acorda Therapeutics Inc (NASDAQ:ACOR), Athersys, Inc. (NASDAQ:ATHX).
Houston, TX – April 16, 2013 — (Net PR News) – AnotherWinningTrade.com, the leader for breaking information and up-to-date market activities on Wall Street, locates high-growth equity opportunities. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.
Today’s focus is on: Genetic Technologies Limited (ADR) (NASDAQ:GENE), Theravance Inc (NASDAQ:THRX), Acorda Therapeutics Inc (NASDAQ:ACOR), Athersys, Inc. (NASDAQ:ATHX)
Genetic Technologies Limited (ADR) (NASDAQ:GENE) surged +22.77% with the closing price of $2.75. The overall volume in the last trading session was 1.80 million shares. Its fifty two week range was $2.00-$6.20. The total market capitalization remained $1.80 million. Other key statistics show that GENE is ahead of its 52 week low 37.50% and its last month price volatility remained 14.71%. Its beta coefficient was 1.33 with a target price of $1.50. In its share capital, GENE has 15.85 million outstanding shares, while 8.75 million shares have been floated in the market.
How Should Investors Trade GENE Now? Don’t Miss out on a Special Trend Analysis
Theravance Inc (NASDAQ:THRX) reported the gain of +19.36% to close at $28.36 in the last trading session and its total traded volume was 4.74 million shares. THRX has market cap of 2.79 billion and its beta value stands at 1.39 times. Theravance, Inc. (Theravance) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas, including respiratory disease, bacterial infections, and central nervous system (CNS)/pain.
What THRX’s Charts Are Signaling for Traders? Find Out Here
Acorda Therapeutics Inc (NASDAQ:ACOR) shares went up +12.63% and closed at $35.50 in the last trading session with the overall traded volume of 1.85 million shares. ACOR has earnings per share of $3.82 and its price to earnings ratio is 9.30. Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system.
Should ACOR be a Buy or Sell Now? Find Out Here
Athersys, Inc. (NASDAQ:ATHX) gained +8.47% to close at $2.05 and its total volume in the last trading session was 1.68 million shares. Stock price 52 weeks high was $2.07 and 52 weeks low price was $0.95. Athersys, Inc. is a United States-based company that develops therapeutic products for the treatment of life threatening and other types of diseases. The Company produces therapeutic proteins, validates biological targets for development and conducts screening for gene discovery.
Can ATHX Show a Strong Recovery? Find out in This Research Report
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.